- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07297745
Essai de l'hybride d'aldostérone pour guider le traitement curable de l'hyperaldostéronisme primaire
Essai de l'hybride de stéroïde d'aldostérone pour guider le traitement curable de l'hyperaldostéronisme primaire
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Primary Aldosteronism is a common but under-diagnosed condition, despite being a curable cause of secondary hypertension with significant long-term health consequences if left untreated. Once the diagnosis of primary aldosteronism is confirmed, subtype tests are required to demonstrate unilateral primary aldosteronism before curative surgery. Most patients need to undergo adrenal vein sampling, an invasive procedure performed under radiological guidance. However, this procedure is technically-challenging, with failure to cannulate both adrenal veins frequently leading to inconclusive results. Many patients worldwide may be offered surgery based on computed tomography imaging alone because of a lack of adrenal vein sampling expertise or a failed adrenal vein sampling result.
High hybrid hormones indicate a functional KCNJ5-mutant aldosterone-producing adenoma and, when coupled with computed tomography imaging, may provide a non-invasive alternative to adrenal vein sampling for identifying unilateral primary aldosteronism.
Ultimately, this trial aims to reduce the number of patients that will require an invasive adrenal vein sampling in future clinical diagnostics. This will improve access, and allow more patients to receive timely and curative treatment.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Troy H Puar, FRCP, PhD
- Numéro de téléphone: 67888833
- E-mail: troy_puar@cgh.com.sg
Lieux d'étude
-
-
-
Singapore, Singapour
- Recrutement
- National University Hospital
-
Contact:
- Ada Teo
- Numéro de téléphone: +65 6908 2222
- E-mail: ada_ed_teo@nuhs.edu.sg
-
Chercheur principal:
- Ada Teo
-
Singapore, Singapour
- Recrutement
- Singapore General Hospital
-
Contact:
- Swee Du Soon
- Numéro de téléphone: +65 6222 3322
- E-mail: swee.du.soon@singhealth.com.sg
-
Chercheur principal:
- Swee Du Soon
-
Singapore, Singapour
- Pas encore de recrutement
- Khoo Teck Puat Hospital
-
Contact:
- Niyati Jauhar
- Numéro de téléphone: +65 6555 8000
- E-mail: jauhar.niyati@nhghealth.com.sg
-
Chercheur principal:
- Niyati Jauhar
-
Singapore, Singapour
- Pas encore de recrutement
- Tan Tock Seng Hospital
-
Contact:
- Lai Tian Rui Ray
- Numéro de téléphone: +65 6357 3078
- E-mail: ray.tr.lai@nhghealth.com.sg
-
Chercheur principal:
- Lai Tian Rui Ray
-
Singapore, Singapour
- Recrutement
- Sengkang General Hospital
-
Contact:
- Matthew Chuah
- Numéro de téléphone: +65 6930 5000
- E-mail: matthew.chuah@singhealth.com.sg
-
Chercheur principal:
- Matthew Chuah Bingfeng
-
-
Singapore
-
Singapore, Singapore, Singapour, 529889
- Recrutement
- Changi General Hospital
-
Contact:
- Troy H Puar, FRCP, PhD
- Numéro de téléphone: +65 68503967
- E-mail: troy_puar@cgh.com.sg
-
Chercheur principal:
- Troy H Puar, FRCP, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Confirmed diagnosis of primary aldosteronism according to the Endocrine Society guideline 2025.
- Willing to undergo subtype testing with adrenal vein sampling and/or molecular imaging (Positron Emission Tomography/Computed Tomography, PET/CT).
- Keen for surgical treatment if shown to have unilateral primary aldosteronism.
Exclusion Criteria:
- Inability to provide written informed consent.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Hybrid hormones
Previous studies have shown that hybrid hormones are elevated in patients with unilateral primary aldosteronism who have large, visible adenomas in their adrenal glands. These tumors harbour a somatic KCNJ5 mutation and are also most likely to be cured of hypertension after surgery. Hence, the investigators hypothesize that high hybrid hormones levels, in the presence of an adenoma on a computed tomography imaging would identify study participants who can proceed to surgery. |
Participants will have a baseline blood sample taken so the investigators can measure the adrenal steroid biomarkers 18-oxocortisol, 18-hydroxylcortisol and other steroids. The collected plasma or serum will then be analyzed in the laboratory using validated methods, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), to determine the levels of these biomarkers. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants with complete biochemical success after unilateral adrenalectomy for unilateral primary aldosteronism using Primary Aldosteronism Surgical Outcome (PASO) measured at least six months post-adrenalectomy.
Délai: 6 months
|
Proportion of participants with correction of hypokalaemia and normalisation of aldosterone-renin-ratio following unilateral adrenalectomy, as per PASO criteria. |
6 months
|
|
Proportion of participants with KCNJ5-mutant aldosterone producing adenoma/nodule
Délai: 6 months
|
Proportion of participants with histopathology and genetic confirmation of KCNJ5-mutant aldosterone producing adenoma/nodule in resected adrenals. |
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants with complete clinical success after unilateral adrenalectomy for unilateral primary aldosteronism using Primary Aldosteronism Surgical Outcome (PASO) measured at least six months post-adrenalectomy.
Délai: 6 months
|
Proportion of participants with reduction in blood pressure and reduction anti-hypertensive medication following unilateral adrenalectomy, as per PASO criteria. |
6 months
|
|
Cost-effectiveness of using hybrid hormones coupled with computed tomography imaging versus other subtyping tests including adrenal vein sampling and/or molecular imaging in diagnosing participants with unilateral primary aldosteronism
Délai: 6 months
|
Cost-effectiveness of the diagnostic course will be calculated by using calculated costs per quality-adjusted life years (QALYs) |
6 months
|
|
Diagnostic criteria using hybrid hormones/ steroid profiling coupled with computed tomography imaging
Délai: 6 months
|
The criteria of hybrid hormones/ steroid profiling coupled with computed tomography imaging which offer the best sensitivity and specificity for lateralization of aldosterone-producing adenoma. |
6 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Troy Puar, FRCP, PhD, Changi General Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TARGET-PA
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .